168 related articles for article (PubMed ID: 24011025)
1. Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.
Ferrer-Marín F; Bellosillo B; Martínez-Avilés L; Soler G; Carbonell P; Luengo-Gil G; Caparrós E; Torregrosa JM; Besses C; Vicente V
J Hematol Oncol; 2013 Sep; 6():68. PubMed ID: 24011025
[TBL] [Abstract][Full Text] [Related]
2. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
Engle EK; Fisher DA; Miller CA; McLellan MD; Fulton RS; Moore DM; Wilson RK; Ley TJ; Oh ST
Leukemia; 2015 Apr; 29(4):869-76. PubMed ID: 25252869
[TBL] [Abstract][Full Text] [Related]
3. ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis.
Guo Y; Zhou Y; Yamatomo S; Yang H; Zhang P; Chen S; Nimer SD; Zhao ZJ; Xu M; Bai J; Yang FC
Leukemia; 2019 May; 33(5):1287-1291. PubMed ID: 30651633
[No Abstract] [Full Text] [Related]
4. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.
Helbig G; Wieczorkiewicz A; Woźniczka K; Wiśniewska-Piąty K; Rusek A; Kyrcz-Krzemień S
Med Oncol; 2012 Dec; 29(4):2379-84. PubMed ID: 22383244
[TBL] [Abstract][Full Text] [Related]
5. Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720-2A>G variant.
Kanduła Z; Kroll-Balcerzak R; Lewandowski K
J Clin Lab Anal; 2022 May; 36(5):e24388. PubMed ID: 35435261
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
[TBL] [Abstract][Full Text] [Related]
7. Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation.
Jurisic V; Pavlovic S; Colovic N; Colovic M
Med Oncol; 2013 Mar; 30(1):398. PubMed ID: 23297051
[No Abstract] [Full Text] [Related]
8. ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden.
Wang YH; Lin CC; Lee SH; Tsai CH; Wu SJ; Hou HA; Huang TC; Kuo YY; Yao M; Chang K; Lin CW; Lin YC; Tien FM; Chou WC; Tang JL; Tien HF
Blood Cancer J; 2020 Oct; 10(10):99. PubMed ID: 33046688
[No Abstract] [Full Text] [Related]
9. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
Beer PA; Delhommeau F; LeCouédic JP; Dawson MA; Chen E; Bareford D; Kusec R; McMullin MF; Harrison CN; Vannucchi AM; Vainchenker W; Green AR
Blood; 2010 Apr; 115(14):2891-900. PubMed ID: 20008300
[TBL] [Abstract][Full Text] [Related]
10. ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.
Valikhani A; Poopak B; Ferdowsi S; Azizi Tabesh G; Ghaffari SH; Saraf Kazeruoni E; Rezaei N; Farshchi A; Amirizadeh N
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e41-e47. PubMed ID: 27640403
[TBL] [Abstract][Full Text] [Related]
11. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
Yoshiki Y; Asai T; Ichikawa M; Hangaishi A; Ota S; Imai Y; Takahashi T; Kurokawa M
Intern Med; 2011; 50(21):2649-52. PubMed ID: 22041374
[TBL] [Abstract][Full Text] [Related]
12. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.
Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N
Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone.
Verger E; Rattarittamrong E; Letort G; Raffoux E; Cassinat B; Kiladjian JJ
Leuk Lymphoma; 2017 Mar; 58(3):749-751. PubMed ID: 27562925
[No Abstract] [Full Text] [Related]
14. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
15. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
16. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.
Tefferi A; Jimma T; Sulai NH; Lasho TL; Finke CM; Knudson RA; McClure RF; Pardanani A
Leukemia; 2012 Mar; 26(3):475-80. PubMed ID: 21912393
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.
Pei YQ; Wu Y; Wang F; Cui W
Ann Hematol; 2016 Sep; 95(9):1391-8. PubMed ID: 27376361
[TBL] [Abstract][Full Text] [Related]
18. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
19. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
[No Abstract] [Full Text] [Related]
20. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms.
Wang X; LeBlanc A; Gruenstein S; Xu M; Mascarenhas J; Panzera B; Wisch N; Parker C; Goldberg JD; Prchal J; Hoffman R; Najfeld V
Exp Hematol; 2009 Oct; 37(10):1194-200. PubMed ID: 19615425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
